



Supplementary figure S1.

a) Resistant patients


*KRAS*: NM\_004985.4: c.34G>T; p.(G12C) (P11)



*KRAS*: NM\_004985.4: c.182A>T; p.(Q61L) (P39)




*NRAS*: NM\_002524.4: c.34G>A; p.(G12S) (P51)




NRAS: NM\_002524.4: c.38G>A; p.(G13D)

P55




P57




BRAF: NM\_004333.5: c.1799T>A; p.(V600E)


P3




P39




P55



P64




PIK3CA: NM\_006218.3: c.1633G>A; p.(E545K) (P63)




**b) Sensitive patients**


*KRAS: NM\_004985.4: c.437C>T; p.(A146V) (P28)*




*BRAF: NM\_004333.5: c.1780G>A; p.(D594N) (P45)*



*BRAF: NM\_004333.5: c.1397G>C; p.(G466A) (P59)*




PIK3CA: NM\_006218.3: c.1633G>A; p.(E545K) (P66)




Supplementary figure S2.

IGF1R: NM\_001291858.1: c.2003T>A; p.(I668N)


P4



P9




P10




IGF1R: NM\_001291858.1: c.3652G>A; p.(E1218K)


P1




P2



P9




P61




IRS2: NM\_003749.2: c.3467C>T; p.(T1156M)


P12



P14




P57




LRIG1: NM\_015541: c.456G>A; p.(T152T)

P12







P57



P63




P67




LRIG2: NM\_014813.2: c.2090C>T; p.(S697L)


P1



P10




P12




LRIG3: NM\_001136051.2: c.2434G>A; p.(V812M)


P1



P2




P9




NRAS: NM\_002524.3: c.344del; p.(G115Efs\*46)


P9



P10




P63




*PDGFRA: NM\_001347828: c.903G>A; p.T301T*

*P52*



*P63*



*P67*

